Truist Financial Raises DaVita (NYSE:DVA) Price Target to $250.00

DaVita (NYSE:DVA) had its price objective upped by stock analysts at Truist Financial from $205.00 to $250.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s target price indicates a potential upside of 6.57% from the stock’s current price.

Several other research analysts have also weighed in on DVA. TD Cowen upped their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. UBS Group raised their price objective on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday. Barclays upped their target price on DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $216.50.

DaVita Stock Performance

DaVita stock opened at $234.59 on Tuesday. The company has a 50 day moving average price of $206.11 and a 200 day moving average price of $161.48. DaVita has a 52 week low of $101.00 and a 52 week high of $239.64. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of 21.75, a P/E/G ratio of 0.76 and a beta of 0.88.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts forecast that DaVita will post 15.07 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DVA. Root Financial Partners LLC raised its stake in shares of DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after purchasing an additional 165 shares during the period. Caitlin John LLC acquired a new position in DaVita during the fourth quarter valued at approximately $34,000. Sankala Group LLC acquired a new position in DaVita during the fourth quarter valued at approximately $39,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of DaVita in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.